SERA PROGNOSTICS, INC.(SERA)Stock Analysis
AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →13F Pro Quality Score
Rank #2,960 of 2,961 stocks
Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Nov 14, 2026.
Revenue Growth
Profitability
Balance Sheet
Earnings Quality
Free Cash Flow
Institutional Flow
Revenue Scale
Dilution Risk
SERA Stock Analysis & AI Quality Score
Data updated 2026-09-11AI stock analysis and institutional research for SERA PROGNOSTICS, INC. (SERA), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores SERA at 3.1/100 on a 32-signal composite quality model, placing it at rank #2,960 of 2,961 stocks — the bottom half of the AI-ranked universe. Areas of concern include free cash flow (0.1) and revenue scale (0.1), which score below median versus the broader universe. Shareholder dilution risk is elevated at 0.2/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q2 2026), SERA PROGNOSTICS, INC. reports quarterly revenue of $30.0K, net income of $-9.1M, free cash flow of $-6.3M. Top institutional holders of SERA by reported 13-F value include BAKER BROS. ADVISORS, Whetstone Capital Advisors, abrdn plc, based on the most recent SEC filings. SERA trades on the Nasdaq exchange and files with the SEC under CIK 1534969. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate SERA daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for SERA PROGNOSTICS, INC. directly from SEC EDGAR. SERA PROGNOSTICS, INC.'s 13F Pro composite quality score has ranged between 3 and 29 since 2022, currently 3.1 — a declining long-term trajectory across 36 quarterly and live scoring snapshots.
Revenue
Q2 2026
$30.0K
Net Income
Q2 2026
$-9.1M
Free Cash Flow
Q2 2026
$-6.3M
ROIC
Q2 2026
-67.4%
Revenue & Net Income
Earnings Per Share
Key Financials Over Time
Export Financial Table · ProRevenue
+5.2% YoYNet Income
+2.9% YoYOperating Income
+0.4% YoYEPS (Diluted)
+32.3% YoYTotal Assets
+40.5% YoYOp. Cash Flow
-80.6% YoYFree Cash Flow
-85.0% YoY| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Revenue | $81.0K +5.2% | $77.0K -74.8% | $306.0K +14.2% | $268.0K +226.8% | $82.0K +228.0% | $25.0K |
| Net Income | $-31.9M +2.9% | $-32.9M +9.2% | $-36.2M +18.0% | $-44.2M -26.2% | $-35.0M -76.4% | $-19.8M |
| Operating Income | $-36.5M +0.4% | $-36.6M +8.0% | $-39.8M +12.8% | $-45.7M -29.0% | $-35.4M -97.0% | $-18.0M |
| EPS (Diluted) | $-0.67 +32.3% | $-0.99 +14.7% | $-1.16 +18.9% | $-1.43 +38.6% | $-2.33 +81.7% | $-12.76 |
| Total Assets | $101.9M +40.5% | $72.6M -24.0% | $95.4M -18.0% | $116.3M -20.9% | $147.0M +893.7% | $14.8M |
| Operating Cash Flow | $-25.6M -80.6% | $-14.2M +47.8% | $-27.2M +21.4% | $-34.6M -9.4% | $-31.6M -87.6% | $-16.9M |
| Free Cash Flow | $-26.3M -85.0% | $-14.2M +47.9% | $-27.3M +22.8% | $-35.4M -7.5% | $-32.9M -93.6% | $-17.0M |
Get alerted when SERA's score changes
Free account: watchlist tracking, the daily AI brief, and the AI screener.
Available Research
13F Pro tracks comprehensive data for SERA PROGNOSTICS, INC. including:
Top Institutional Holders of SERA
BAKER BROS. ADVISORS LP
$10.0M5,498,170 shWhetstone Capital Advisors, LLC
$6.0M3,306,889 shabrdn plc
$5.0M2,753,525 shVivo Capital, LLC
$3.0M1,650,440 shVANGUARD CAPITAL MANAGEMENT LLC
$2.4M1,297,792 shCAPTRUST FINANCIAL ADVISORS
$975.1K535,755 shGEODE CAPITAL MANAGEMENT, LLC
$635.5K348,967 shBlackRock, Inc.
$402.9K221,369 shAWM Investment Company, Inc.
$377.4K207,382 shVANGUARD FIDUCIARY TRUST CO
$311.1K170,908 sh
| Fund | Value | Shares |
|---|---|---|
| BAKER BROS. ADVISORS LP | $10.0M | 5,498,170 |
| Whetstone Capital Advisors, LLC | $6.0M | 3,306,889 |
| abrdn plc | $5.0M | 2,753,525 |
| Vivo Capital, LLC | $3.0M | 1,650,440 |
| VANGUARD CAPITAL MANAGEMENT LLC | $2.4M | 1,297,792 |
| CAPTRUST FINANCIAL ADVISORS | $975.1K | 535,755 |
| GEODE CAPITAL MANAGEMENT, LLC | $635.5K | 348,967 |
| BlackRock, Inc. | $402.9K | 221,369 |
| AWM Investment Company, Inc. | $377.4K | 207,382 |
| VANGUARD FIDUCIARY TRUST CO | $311.1K | 170,908 |
Companies Similar to SERA
Ranked by quality-profile closeness and shared hedge-fund ownership — not just sector membership.
PRECISION BIOSCIENCES INC
Centessa Pharmaceuticals plc
Avalo Therapeutics, Inc.
Dianthus Therapeutics, Inc. /DE/
DBV Technologies S.A.
Taysha Gene Therapies, Inc.
Xencor Inc
IDEAYA Biosciences, Inc.
Similarity is computed from the 8 composite sub-scores and latest-quarter 13F conviction holdings (index-style filers excluded). Refreshed monthly.
More Healthcare Companies
View all Healthcare →Put SERA on your watchlist
Track score changes the day SERA PROGNOSTICS, INC. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.
Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).
Popular Research
Is SERA a good stock to buy?
13F Pro's AI-powered analysis of SERA PROGNOSTICS, INC. (SERA) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for SERA are available on the SERA stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing. SERA is classified as a small company.
Which hedge funds own SERA?
Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling SERA. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of SERA PROGNOSTICS, INC.'s investment landscape.